Bruce G Mccarthy

Title: Bruce G. McCarthy: Innovator in Respiratory Treatment

Introduction

Bruce G. McCarthy is an accomplished inventor based in the United States. He has made significant contributions to the field of respiratory treatment through his innovative work. His research focuses on developing compounds that target specific receptors involved in cough reflex mechanisms.

Latest Patents

Bruce G. McCarthy holds a notable patent titled "Diaminopyrimidine P2X3 and P2X2/3 Receptor Modulators for Treatment of Acute, Sub-Acute or Chronic Cough." This invention pertains to diaminopyrimidine compounds that act as antagonists of P2X purinergic receptors. The methods outlined in the patent involve administering an effective amount of these compounds to treat diseases associated with P2X receptors. More specifically, the patent addresses the use of P2X3 and/or P2X2/3 antagonists in managing cough, chronic cough, and the urge to cough in various respiratory conditions and disorders.

Career Highlights

Bruce G. McCarthy is currently associated with Afferent Pharmaceuticals, Inc., where he continues to advance his research in respiratory therapies. His work has the potential to significantly impact the treatment of cough-related disorders, providing new avenues for patient care.

Collaborations

One of his notable collaborators is Anthony P. Ford, with whom he has worked closely on various projects related to respiratory treatments.

Conclusion

Bruce G. McCarthy's innovative contributions to respiratory treatment highlight his dedication to improving patient outcomes. His work in developing P2X receptor modulators represents a significant advancement in the field.